Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: a large prospective study phenotyping perioperative myocardial injury after arterial vascular surgery and linking etiologies to stark 1-year outcomes; a UK Biobank analysis showing accelerated biological aging markedly increases incident valvular heart disease risk with additive effects from polygenic risk; and a pooled analysis from five heart failure trials introducing cumulative resting heart rate load as a superior prognostic metric.
Summary
Three impactful cardiology studies stood out: a large prospective study phenotyping perioperative myocardial injury after arterial vascular surgery and linking etiologies to stark 1-year outcomes; a UK Biobank analysis showing accelerated biological aging markedly increases incident valvular heart disease risk with additive effects from polygenic risk; and a pooled analysis from five heart failure trials introducing cumulative resting heart rate load as a superior prognostic metric.
Research Themes
- Perioperative cardiac risk phenotyping and outcomes after vascular surgery
- Biological aging and genetic risk in valvular heart disease
- Heart rate dynamics as a prognostic biomarker in chronic heart failure
Selected Articles
1. Prevalence, phenotypes, and long-term outcomes of cardiac complications after arterial vascular surgery.
In 2,265 high-risk arterial vascular surgery patients, perioperative myocardial injury occurred in 18.7% with marked etiologic heterogeneity. One-year outcomes varied substantially by phenotype: extracardiac PMI, tachyarrhythmia, and postoperative acute heart failure had especially high mortality and MACE compared with patients without PMI.
Impact: This study provides rigorous, centrally adjudicated phenotyping of perioperative myocardial injury and links etiologies to stark differences in 1-year mortality, informing triage and management priorities.
Clinical Implications: Cardiac damage phenotyping can guide prioritization on surgical waitlists, surveillance intensity, and targeted management (eg, addressing extracardiac precipitants, early rhythm control or heart failure therapy), potentially reducing wait-list failure and improving outcomes.
Key Findings
- Perioperative myocardial injury occurred in 18.7% (423/2,265) after arterial vascular surgery.
- One-year mortality and MACE rates differed markedly by PMI etiology: extracardiac PMI had 67% mortality and 63% MACE; tachyarrhythmia and postoperative acute heart failure each had ~45–47% mortality and ~73% MACE.
- Patients without PMI had substantially lower 1-year mortality (8%) and MACE (10%).
- PMI incidence was highest after open thoracic/thoracoabdominal/abdominal aortic aneurysm repair (42%) and lowest after carotid endarterectomy (11%).
Methodological Strengths
- Prospective inclusion with central adjudication of cardiac events and hierarchical etiologic classification
- Large sample size with 1-year follow-up and clinically meaningful endpoints (mortality and MACE)
Limitations
- Observational design with potential residual confounding and no interventional testing of phenotype-guided strategies
- Generalizability may be limited to high-risk vascular surgery populations and specific procedural mixes
Future Directions: Multicenter validation and randomized evaluation of phenotype-guided management pathways (eg, extracardiac trigger mitigation, early rhythm control or heart failure optimization) are warranted.
OBJECTIVE: The aim of this study prospective diagnostic study with central adjudication was to (1) determine the incidence and phenotypes of cardiac complications after arterial vascular surgery, (2) investigate possible heterogeneity, and (3) assess short- and long-term mortality and major adverse cardiac events (MACEs) according to different phenotypes of these cardiac complications. METHODS: Consecutive high-risk patients (age >65 years or with known cardiovascular disease) undergoing arterial vascular surgery were included between 2014 and 2019. Cardiac complications including perioperative myocardial infarction/injury (PMI) were centrally adjudicated by two independent physicians. PMI etiologies were hierarchically classified into extracardiac if caused by a primarily extracardiac disease such as severe sepsis or pulmonary embolism, or cardiac, and further subtyped into type 1 MI, tachyarrhythmia, postoperative acute heart failure (pAHF), or likely type 2 MI. All-cause death and MACE, including acute MI, pAHF, life-threatening arrhythmia, and cardiovascular death, were assessed during 1-year follow-up. RESULTS: Among 2'265 patients (median age 71 years, 27% female), PMI occurred in 423 (18.7%) with substantial heterogeneity.
2. Accelerated Biological Aging, Genetic Predisposition, and Incident Valvular Heart Disease.
In 341,460 UK Biobank participants free of VHD at baseline, higher biological age acceleration (KDM-BA and PhenoAge) significantly increased incident VHD risk over 13.6 years. The highest quartile of KDM-BA acceleration had an 86% higher risk than the lowest, and biological aging showed additive interaction with polygenic risk.
Impact: This work introduces biological aging acceleration as a robust, quantifiable predictor of incident valvular heart disease and demonstrates gene–environment interplay with polygenic risk.
Clinical Implications: Biological age metrics could augment VHD risk stratification beyond chronological age and genetics, enabling earlier surveillance and preventive strategies for high-risk individuals.
Key Findings
- Among 341,460 participants, 8,146 incident VHD cases occurred over a median 13.58 years.
- Each 1-SD increase in KDM-BA acceleration was associated with HR 1.35 (95% CI: 1.32-1.38); PhenoAge acceleration HR 1.29 (95% CI: 1.26-1.32).
- Top quartile of KDM-BA acceleration had 86% higher VHD risk (HR 1.86; 95% CI: 1.74-1.99) versus lowest quartile.
- Additive interaction was observed between biological age acceleration and polygenic risk score for VHD.
Methodological Strengths
- Very large prospective cohort with long follow-up and robust endpoints
- Use of two independent biological age algorithms and genome-wide PRS with interaction analyses
Limitations
- Observational design limits causal inference; residual confounding and measurement error in biological age metrics possible
- Generalizability beyond UK Biobank demographics requires validation in diverse populations
Future Directions: Validate biological age–based risk scores across diverse cohorts and test whether modifying aging-related pathways reduces VHD incidence.
BACKGROUND: The association between biological aging and valvular heart disease (VHD) has not yet been evaluated. OBJECTIVES: This study aimed to evaluate the associations between 2 biological age indicators, Klemera-Doubal method biological age (KDM-BA) acceleration and PhenoAge acceleration, and the risk of VHD, as well as explore the potential gene-environment interplay. METHODS: The study included 341,460 UK Biobank participants without VHD at enrollment. Biological age was assessed using KDM-BA and PhenoAge methods. Genetic risk was measured by genome-wide-association study-based polygenic risk scores (PRS). Cox models were used to assess the individual and joint effects of biological age and PRS on incident VHD. Both multiplicative and additive interactions between the 2 factors were also estimated. RESULTS: During a median follow-up of 13.58 years (Q1-Q3: 12.83-14.25 years), 8,146 VHD cases were documented. The results showed a significant association between older biological age and an increased risk of VHD, with a HR of 1.35 (95% CI: 1.32-1.38) for each 1-SD increase in KDM-BA acceleration, and 1.29 (95% CI: 1.26-1.32) for PhenoAge acceleration.
3. Cumulative resting heart rate load and cardiovascular risk in patients with heart failure in sinus rhythm.
Across 5 heart failure trials (n=5,428), a new metric—cumulative resting heart rate load (AUC of HR ≥70 bpm)—was independently associated with higher risks of MACE, cardiovascular death, heart failure hospitalization, all-cause death, and any hospitalization. This metric outperformed baseline and mean HR and other HR variability measures in prognostic discrimination.
Impact: Introduces a practical, integrative heart rate metric that captures magnitude and duration of tachycardia, improving risk stratification beyond traditional HR measures in chronic heart failure.
Clinical Implications: Cumulative HR load could be incorporated into routine assessment to identify high-risk patients in sinus rhythm who may benefit from intensified monitoring, HR-modulating therapies, or device-based strategies.
Key Findings
- Cumulative resting HR load (AUC of HR ≥70 bpm) independently predicted MACE (HR 1.31; 95% CI 1.24–1.38) and its components.
- Higher cumulative HR load was associated with cardiovascular death (HR 1.17), HF hospitalization (HR 1.34), all-cause death (HR 1.20), and any hospitalization (HR 1.20).
- Cumulative HR load improved discrimination and reclassification over baseline HR, mean HR, HR SD, and time-in-target metrics.
Methodological Strengths
- Pooled analysis across five randomized trial datasets enhances generalizability within HF populations
- Robust statistical evaluation including C-statistics, NRI, and IDI to compare prognostic performance
Limitations
- Secondary analysis; heart rate measurement schedules and follow-up durations varied across trials
- Observational associations cannot establish causality or define therapeutic thresholds
Future Directions: Prospective validation and interventional studies testing HR load–guided therapy (eg, beta-blockade optimization, device titration) are needed.
INTRODUCTION AND OBJECTIVES: Resting heart rate is a readily available vital sign with important prognostic significance. However, traditional measures overlook both the magnitude and duration of elevated heart rate over time. This study assessed the association between cumulative resting heart rate load and adverse outcomes in patients with chronic heart failure (HF) in sinus rhythm. METHODS: Data from 5 randomized controlled trials (BEST, GUIDE-IT, HF-ACTION, RELAX, and TOPCAT) were analyzed. Cumulative heart rate load was calculated as the area under the curve (AUC) for heart rate ≥70 beats per minute (bpm), relative to the total AUC prior to outcomes. The primary outcome was major adverse cardiac events (MACE), defined as the composite of cardiovascular death and hospitalization for HF. Cox proportional hazards regression models were used to examine associations with outcomes. RESULTS: A total of 5428 patients were included. Higher cumulative resting heart rate load was significantly associated with increased risk of MACE (hazard ratio [HR], 1.31; 95% CI, 1.24-1.38), cardiovascular death (HR, 1.17; 95% CI, 1.08-1.27), hospitalization for HF (HR, 1.34; 95% CI, 1.26-1.43), all-cause death (HR, 1.20; 95% CI, 1.12-1.29), and any hospitalization (HR, 1.20; 95% CI, 1.15-1.25).